Tempus, a leader in artificial intelligence and precision medicine, today announced that Rush University Medical Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers that are leveraging the program to advance its research.
Tempus+ offers researchers a sustainable and secure infrastructure to collect and analyze the data required to foster research that can inform the future of clinical care. Researchers at Rush are leveraging Tempus’ library of more than six million de-identified research records through the company’s data analytics platform, Lens, to identify patterns and insights, define and test their hypotheses, and eventually investigate and potentially publish their research.
“Tempus+ has an enormous potential to make an impact in cancer by using an incredible amount of data to learn about small, yet important subsets of patients, whose molecular subtypes would otherwise be extremely difficult to study,” said Mary Jo Fidler, MD, Professor of Medicine and Section Chief of Medical Oncology at Rush University Medical Center.
“The team at Rush has always been valuable collaborators, and we’re thrilled to have them be a part of the Tempus+ community,” said Mike Thompson, MD, PhD, Vice President of Clinical Partnerships at Tempus.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.